Poorer Outcome in Adults With Localized Ewing Sarcoma Compared With Children
Adults with localized Ewing sarcoma have a much lower rate of 5-year survival than do children.
Changing Paradigms for NSCLC in Personalized Therapy Era
With the discovery of mutation drivers for NSCLC--including EGFR, KRAS, and EMLA 4-ALK--targeted therapies directed to those mutations are beginning to make a difference.
Prostate Cancer Armamentarium Expanding
Men with prostate cancer now have an array of treatments, which was not the case a decade ago.
Brain Metastasis Common in Ovarian Cancer
Half of all women with advanced ovarian cancer who develop brain cancer have a single metastasis to the brain.
Continuing Chemotherapy to Near Death Offers No Benefits in Older Patients With Advanced Lung Cancer
An aggressive approach to care involving the continuation of chemotherapy within 2 weeks of death does not improve survival in elderly patients with metastatic NSCLC.
Lower Rate of Colorectal Cancer Screening May Be Linked to Higher Cancer Fatalism
Higher cancer fatalism, a term that refers to the belief that a cancer diagnosis leads inevitably to death, may be associated with a lower rate of colorectal cancer screening.
Benefit of ADT Added to Radiation Confined to Intermediate- Risk Prostate Cancer Patients With Poor Prognosis
Not all intermediate-risk prostate cancer patients benefit from the addition of androgen deprivation therapy to radiation therapy.
SCLC on the Wane, but Difficult to Treat
Patients with limited and extensive SCLC show incremental gains with different treatment strategies but so far novel agents have failed to make a difference in outcomes.
Axitinib Nears Approval as Second-Line Therapy for Metastatic Renal Cell Carcinoma
Axitinib has shown promising results in phase II and III trials, including the AXIS trial in patients with metastatic clear cell RCC who failed on other treatments.
Men With Colorectal Cancer Often Not Consulted About Risks for Erectile Dysfunction
Men with colorectal cancer are not routinely informed about the potential for erectile dysfunction or how the condition can best be managed.
Tasquinimod Shows Potential for Metastatic Castration-Resistant Prostate Cancer
The investigational compound tasquinimod significantly postpones disease progression and increases PFS in men with minimally symptomatic, metastatic CRPC.
Fertility Treatment Increases Risk of Ovarian Cancer
Subfertile women who undergo ovarian stimulation for in vitro fertilization have an increased risk of ovarian malignancies.
Prediagnosis Primary Care Visits Improve Outcomes in Medicare Patients With Colorectal Cancer
Medicare beneficiaries with CRC who made a higher number of visits to their PCP before their diagnosis had lower disease-related mortality and lower all-cause mortality.
PARP Inhibition Explored in Triple-Negative Breast Cancer
A group of pharmacologic inhibitors of the enzyme poly ADP ribose polymerase, are gaining ground as a potential strategy for treating triple-negative breast cancer.
December 2011: Trials in Progress
The Trials in Progress section supploes summaries of ongoing research in a broad range of cancer types.
NKTR 102 Will Move to a Phase III Trial in Pretreated Metastatic Breast Cancer
A phase II study of NKTR 102 suggest that this agent will find a role in the treatment of patients with heavily pretreated metastatic breast cancer whose disease is progressing.
No Survival Advantage for High-Dose Radiation Versus Standard-Dose Radiation in Stage III NSCLC
High-dose radiation was no better than standard-dose radiation given concurrently with chemotherapy in extending survival of patients with advanced unresectable NSCLC.
Patients With Lung Cancer Often Receive Excess Radiation
Patients undergoing lung resection for NSCLC are frequently exposed to a higher dose of radiation than that which has been deemed safe for healthcare workers.
Danish Study Finds No Link Between Cell Phone Use and Cancer
Danish investigators are reporting that long-term cell phone use does not appear to boost the risk of central nervous system (CNS) tumors.
Exelixis Finds Great Promise in Cabozantinib
The investigational compound cabozantinib (formerly known as XL184) has generated much excitement in recent years for its ability to target multiple pathways involved in the development of cancer.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.